Analysis of Therapix Biosciences manpower and management performance can provide insight into Therapix Biosciences stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Therapix Biosciences future performance. Also please take a look at World Market Map.
Therapix Biosciences Management EffectivenessThe company has return on total asset (ROA) of (37.65) % which means that it has lost $37.65 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (216.64) % meaning that it generated substantial loss on money invested by shareholders.
Therapix Biosciences Stakeholders
|Ascher Shmulewitz Chairman of the Board, Interim CEO|
|Guy Goldin Vice President - Finance|
|Doron Ami Vice President-Strategy|
|Adi ZuloffShani Vice President-Technologies|
|Oz Adler CFO|
|Tamar Kfir Director|
|Yafit Stark Independent Director|
|Ahmed Alimi Director|
|Itamar Shalit Director|
|Zohar Heiblum Independent Director|
|Abraham Meizler Director|
|Amit Berger External Director|
|Einat Zisman Director|
|Mark Groussman Director|
|Itzhak Kobrin Director|
|Eric So Director|
|Stephen Siems Director|
Therapix Biosciences employes about 9 people. The company is managed by 17 executives with total tenure of roughly 80 years, averanging almost 4.0 years of service per executive having 0.0 employee per reported executive.
|Net Loss Per Employee||851.1 K|
|Net Loss Per Executive||450.6 K|